Highest-materiality recent filing
Skye Bioscience stockholders approve 3x increase in authorized common shares to 300M
Charter Amendment increases authorized common shares from 100M to 300M, filed with Nevada on May 28, 2026.
Skye Bioscience receives Nasdaq delisting notice for failing minimum stockholders' equity
Stockholders' equity was $9,011,804, below Nasdaq Global Market's $10M minimum requirement.
Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150
John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
Skye Bioscience receives Nasdaq deficiency notice for bid price below $1.00
Received deficiency letter on March 17, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
Net loss Q4 2025: $14.4M; full year $55.9M; cash & equivalents $25.7M as of Dec 31, 2025.
Nimacimab 200mg + semaglutide 2.4mg achieved 22.3% mean weight loss at 52 weeks; no plateau observed, suggesting further efficacy potential.
Skye Bioscience licenses Halozyme's ENHANZE technology for subcutaneous nimacimab
Non-exclusive license to Halozyme's ENHANZE drug delivery tech for subcutaneous nimacimab formulation.
Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.
Nimacimab monotherapy at 200 mg failed primary endpoint with placebo-subtracted weight loss of -1.26% (p=0.2699, mITT).
Skye Bioscience Q2 net loss $17.6M; Phase 2a top-line data due late Q3/early Q4 2025
Net loss of $17.6M for Q2 2025, vs $7.9M in Q2 2024; R&D expense rose to $14.3M from $4.1M.
Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025
Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.
Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025
Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
Skye Bioscience appoints Puneet Arora as Chief Medical Officer, grants 225,000 stock options
Puneet S. Arora, MD, appointed CMO effective Sept 3, 2024; base salary $475k with 40% target bonus.
Skye Bioscience appoints Dr. Karen Smith to board; two directors resign effective Aug 1
Appoints Dr. Karen Smith MD, PhD, MBA, LLM to board; retainer $40k/yr plus committee fees and 40,000-share option.
Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
Skye Bioscience reports pro forma equity >$5M after $90M private placement
Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
Skye Bioscience raises $40M via PIPE of 4M shares at $10 each
Issued 4,000,000 shares at $10.00 per share for gross proceeds of $40,000,000.
Skye Bioscience appoints Dr. Annalisa Jenkins to board; director Dalesandro to resign Aug 1
Dr. Annalisa Jenkins appointed to board effective Feb 29, 2024, filling newly created eighth seat.
Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance
Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.
Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial
Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.
Skye licenses SBI-100 to Tautomer for Africa, terminates UM 8930 license, sells Canadian lab
Exclusive license to Tautomer for SBI-100 (THC prodrug) suppository in Africa for chronic pain and other indications.
On September 3, 2024, Skye Bioscience, Inc. (the “Company”) announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer, effective as of September 3, 2024 (the “Effective Date”).
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
the Board approved an increase in its authorized size from eight to nine members and appointed Karen L. Smith MD, PhD, MBA, LLM to fill the vacancy created by such increase.
On July 1, 2024, each of Keith Ward, PhD and Praveen Tyle, PhD informed the Board of their intent to resign as a member of the Board, effective August 1, 2024.
Margaret Dalesandro, Ph.D. informed the Board of her intent to resign as a member of the Board, effective August 1, 2024.
appointed Annalisa Jenkins, M.B.B.S., F.R.C.P. to fill the vacancy created by such increase.
Max materiality 0.85 · Median 0.65 · Most common event other_material